Vascular Dissemination Homing and Colonization

Slide 1 · Vascular Dissemination,

Homing, and Colonization

The distant phase of the metastatic cascade

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Distinguish vascular dissemination, tissue homing, extravasation, and colonization.

Explain why circulating tumor cells rarely produce overt metastases.

Interpret vascular drainage, organ tropism, and tumor dormancy.

Trace a tumor–stromal feedback loop in bone metastasis.

Mechanistic lecture with clinicopathologic examples.

Slide 3 · The metastatic cascade has two linked phases

Local ECM invasion

Intravasation

Survival and arrest

Extravasation

Colonization

This lecture emphasizes the vascular and distant-organ phases.

Slide 4 · Invasion and metastasis are distinct properties

Local invasion

Tumor breaches basement membrane and interstitium.

Vascular access becomes possible.

Metastatic spread

Tumor establishes growth at a discontinuous site.

Requires survival and adaptation after dispersal.

Invasion is a prerequisite for many solid-tumor metastases, not a guarantee.

Slide 5 · A journey with sequential bottlenecks

Leave the primary site

Resist hazards in circulation

Arrest in a distant vascular bed

Exit the vessel

Persist and proliferate

A failure at any stage can prevent a clinically apparent metastasis.

Slide 6 · Why hematogenous metastasis is inefficient

Large numbers of locally invasive tumor cells may enter the bloodstream.

Only a small minority give rise to established metastatic tumors.

Success depends on multiple tumor-cell and host-cell interactions.

Many circulating tumor cells ≠ many metastatic lesions.

Slide 7 · Metastatic competence is multifactorial

No single universal “metastasis gene” explains the cascade.

Complementary genetic and epigenetic changes may be needed.

Distinct subclones may provide different required capabilities.

Cooperation within heterogeneous tumor-cell groups is a plausible mechanism.

Slide 8 · The vascular phase begins after intravasation

Basement membrane breached

Endothelial barrier crossed

Tumor cells enter blood

Cells encounter circulating defenses

Intravasation follows local ECM degradation and migration.

Slide 9 · Blood exposes tumor cells to three major threats

Mechanical shear stress during circulation.

Anoikis, apoptosis induced by loss of appropriate anchorage.

Innate and adaptive immune defense mechanisms.

Survival in blood is an active biological challenge.

Slide 10 · Shear stress threatens circulating tumor cells

Schematic: Circulating malignant cells and blood elements

Blood flow

Fluid flow creates mechanical forces on freely circulating cells.

The vascular environment differs from a protected tissue niche.

Slide 11 · Anoikis is the price of losing anchorage

Normal epithelial cell

Loses attachment to extracellular matrix.

May activate apoptosis (anoikis).

Metastatic tumor cell

Must resist attachment-loss signals.

May use altered integrin-associated survival signaling.

Anoikis resistance assists survival after detachment.

Slide 12 · Immune defenses remain a systemic barrier

Innate responses and adaptive responses can destroy circulating cancer cells.

Metastasizing cells must evade surveillance while traveling through blood.

Immune evasion is one challenge among several, not the complete explanation.

The source identifies defense categories; Specific checkpoints are outside this unit.

Slide 13 · Viability is not the same as metastatic competence

Viable circulating cell

Has survived hazards of the bloodstream.

May still lack traits needed for distant growth.

Metastasis-forming cell

Must arrest, extravasate, and persist.

Must adapt to a novel tissue environment.

Circulating tumor cells are detectable, but not all are founders of metastases.

Slide 14 · A circulating tumor cell may travel alone

Schematic: Circulating malignant cells and blood elements

Blood flow

Individual cells can be exposed to blood-borne stresses.

Single-cell dissemination does not establish that colonization will occur.

Slide 15 · Multicellular aggregates offer a potential advantage

Schematic: Circulating malignant cells and blood elements

Homotypic cell cluster

Tumor cells can travel as cohesive multicellular groups.

Evidence favoring aggregates among metastatic founders.

Slide 16 · Two types of cell–cell interaction form emboli

Homotypic

Tumor cell ↔ tumor cell.

Creates cohesive cancer-cell aggregates.

Heterotypic

Tumor cell ↔ circulating blood element.

Platelets are especially emphasized.

Both interactions can support circulating tumor-cell clumping.

Slide 17 · Platelets interact with tumor-cell aggregates

Schematic: Circulating malignant cells and blood elements

Platelet-associated aggregate

Platelets associate with tumor cells in the blood.

These interactions are believed to enhance tumor-cell survival.

Slide 18 · A coagulation-linked route to tumor emboli

Tumor-cell polyphosphate

Factor XII (contact) activation

Fibrin deposition

Tumor embolus stabilization

This as a possible mechanism, not a universal feature.

Slide 19 · Polyphosphate is one proposed initiator

Some tumors express anionic substances such as polyphosphate.

Polyphosphate may activate factor XII in the contact pathway.

This can lead to local fibrin deposition around aggregates.

Use conditional language: “some,” “may,” and “potentially.”

Slide 20 · Fibrin can consolidate tumor emboli

Schematic: Circulating malignant cells and blood elements

Fibrin deposition (schematic)

Stabilized tumor embolus

Fibrin deposition may stabilize a multicellular embolus.

Stabilized emboli may arrest together in capillary beds.

Slide 21 · Why arresting as a group might matter

Circulating single cell

Must independently withstand bloodstream stress.

Must individually possess founder capabilities.

Circulating cell group

Can aggregate with platelets and fibrin.

May collectively supply complementary traits.

These are mechanistic proposals, not guarantees of clinical metastasis.

Slide 22 · Clusters may contain complementary subclones

Different tumor cells may contribute different metastasis-related traits.

Collaborative migration can therefore be biologically advantageous.

Collective behavior is compatible with tumor heterogeneity.

The specific contribution of each subclone cannot be presumed.

Slide 23 · Stem cell–like traits matter to metastatic founders

Self-renewing cells may sustain prolonged growth at a distant site.

Plasticity may help adaptation to a foreign microenvironment.

A cell group may be more likely to contain needed stem cell–like capabilities.

Stemness is a proposed component of successful colonization.

Slide 24 · From aggregate formation to vascular arrest

Tumor cells aggregate

Platelets interact

Fibrin may stabilize

Emboli arrest in capillaries

Arrest is an intermediate stage; Extravasation and outgrowth must follow.

Slide 25 · Three determinants of metastatic distribution

Vascular drainage from the primary

Organ-specific tumor tropism

Escape from tumor dormancy

These govern where circulating cells stop and which deposits become clinically significant.

Slide 26 · Vascular drainage provides a first-pass filter

Tumor cells enter vessels connected to the primary tumor.

The first downstream capillary bed can trap disseminated cells.

Lung and liver are common sites in the first-pass framework.

Anatomical blood flow predicts some—but not all—patterns.

Slide 27 · Colon carcinoma illustrates portal drainage

Primary colon carcinoma

Portal venous drainage

Liver vascular bed

Frequent liver metastasis

The liver is the first major organ downstream for many colorectal primaries.

Slide 28 · The “first capillary bed” principle

Anatomical factor

Expected implication

Important qualification

Venous drainage

Directs circulating cells downstream

Does not explain all tropisms

Capillary arrest

Can retain tumor emboli

Arrest is not outgrowth

Liver and lung

Common first-pass destinations

Other organs may be preferred

Both anatomy and tumor biology influence distribution.

Slide 29 · Anatomy alone cannot account for tropism

Several cancers preferentially metastasize to particular organs.

Those preferences cannot be reduced to first-pass vascular trapping.

Adhesion, chemotaxis, and tissue permissiveness provide additional explanations.

Do not confuse circulation pathways with organ-specific biological selection.

Slide 30 · Classic organ-tropism examples

Primary neoplasm

Favored metastatic sites

Prostate carcinoma

Bone

Breast carcinoma

Bone

Lung carcinoma

Adrenal glands; brain

Neuroblastoma

Liver; bone

Ocular melanoma

Liver

Examples are tendencies, not exclusive metastatic destinations.

Slide 31 · Breast and prostate carcinomas favor bone

Bone is a characteristic target for these tumors.

This is a departure from a drainage-only prediction.

Later slides explain a breast cancer–bone microenvironment feedback mechanism.

A favored site does not imply that every tumor follows this route.

Slide 32 · Lung carcinoma may involve adrenals and brain

The source highlights adrenal and brain metastases from lung carcinoma.

Organ-specific preferences suggest mechanisms beyond simple trapping.

Brain endothelium is additionally relevant to extravasation biology.

Site patterns motivate mechanistic questions; They are not diagnostic rules.

Slide 33 · Neuroblastoma and ocular melanoma show tropism

Neuroblastoma is described as spreading to liver and bone.

Ocular melanoma has a striking tendency to metastasize to liver.

Both illustrate selective destination patterns across tumor types.

“Seed” characteristics and “soil” characteristics must be considered together.

Slide 34 · Three complementary biological explanations

Endothelial adhesion molecule matching

Chemokine-guided cell trafficking

Supportive destination microenvironment

Any one mechanism is not established as a universal determinant.

Slide 35 · Adhesion receptors can mediate tissue targeting

Tumor adhesion molecule

Ligand on organ endothelium

Preferential vascular interaction

Potential organ homing

Specific receptor–ligand matching may favor colonization of particular organs.

Slide 36 · CD44 links normal trafficking to cancer homing

CD44 is expressed on normal T lymphocytes.

It participates in selective lymphocyte migration to lymphoid tissues.

Solid cancers often express CD44, potentially enhancing dissemination.

This example illustrates reuse of normal cell-trafficking machinery.

Slide 37 · CD44 and hyaluronate: The physiological model

CD44 on T lymphocyte

Binding to hyaluronate

High endothelial venule

Selective lymphoid homing

The physiologic receptor–ligand example motivates tumor homing models.

Slide 38 · CD44 in normal and malignant settings

Normal immune trafficking

CD44-bearing T lymphocytes.

Hyaluronate on high endothelial venules.

Solid-tumor dissemination

CD44 often expressed by tumor cells.

Expression appears to facilitate lymph node and other spread.

Association with spread does not alone prove an organ-specific causal mechanism.

Slide 39 · Chemokine gradients may help direct cancer cells

Chemokine in destination tissue

Cancer-cell chemokine receptor

Directed movement / homing

Preferential target-site access

This parallels chemokine-directed trafficking of immune cells.

Slide 40 · Adhesion versus chemokine guidance

Adhesion-based homing

Receptor engages an endothelial ligand.

Promotes selective vascular attachment.

Chemokine-based homing

Receptor detects a tissue chemoattractant.

Can influence tumor-cell movement.

Both are plausible contributors to organ tropism.

Slide 41 · The seed–soil model concerns compatibility

Cancer-cell “seed”

Distant-organ “soil”

Biological compatibility

Outgrowth if permissive

Stephen Paget’s hypothesis emphasizes colonization, not simply blood flow.

Slide 42 · A well-perfused site may still resist metastasis

Permissive soil

Supports cancer-cell persistence.

Can provide tumor-supporting signals.

Nonpermissive soil

Unfavorable for distant tumor growth.

May remain metastasis-poor despite vascular supply.

Skeletal muscle and spleen are textbook examples of relatively nonpermissive sites.

Slide 43 · Skeletal muscle illustrates nonpermissive soil

Skeletal muscle receives substantial blood flow.

Yet metastatic deposits are comparatively unusual there.

This mismatch challenges a purely hemodynamic explanation.

A tissue can receive tumor cells but fail to support expansion.

Slide 44 · The spleen illustrates the same paradox

The spleen is richly vascularized.

Nevertheless, metastases as relatively rare.

Blood delivery does not imply successful seeding and colonization.

The primary teaching point is tissue permissiveness, not absolute immunity.

Slide 45 · Separate arrival from establishment

Process

Question

What it establishes

Vascular delivery

Do cells reach the organ?

Opportunity for arrest

Adhesion / chemotaxis

Do cells preferentially interact?

Potential tissue tropism

Local microenvironment

Can cells survive and grow?

Productive colonization

Dormancy escape

Do surviving cells expand?

Clinically apparent metastasis

These stages are related but not interchangeable.

Slide 46 · Extravasation begins after vascular arrest

Arrest at target site

Transmigration between endothelial cells

Basement membrane egress

Entry into organ parenchyma

Extravasation is tissue entry; It does not itself establish a growing lesion.

Slide 47 · Tumor cells must cross an endothelial barrier

Schematic tissue entry after capillary arrest

Vessel lumen

Extravascular tissue

Vascular basement membrane

Cells exit through or between elements of the vessel lining.

They then traverse the endothelial basement membrane.

Slide 48 · Adhesion molecules assist extravasation

Integrins participate in adhesion during distant tissue entry.

Laminin receptors can contribute to basement-membrane interactions.

Successful passage depends on coordinated cell–matrix interactions.

This mirrors, but is not identical to, local tumor-cell invasion.

Slide 49 · Proteases enable movement through barriers

Adhesion to local structures

Proteolytic activity

Remodeling of ECM / basement membrane

Tissue egress

The source identifies proteases as required effectors without a universal enzyme list.

Slide 50 · Chemokines also influence extravasation

Chemokines may originate from cancer cells.

They may also be supplied by host innate immune cells.

Their effects can assist movement into the extravascular compartment.

Source emphasizes multiple interacting cell populations.

Slide 51 · Tumor cells are not the only cellular actors

Cancer cells

Provide adhesion receptors and proteases.

May produce chemokines.

Innate immune cells

Monocytes and neutrophils contribute signals.

Can provide chemokines that facilitate extravasation.

The tissue-entry process is a tumor–host interaction.

Slide 52 · Endothelial architecture changes the challenge

Fenestrated endothelium

Representative sites: Liver and bone marrow.

Structural context may affect cell passage.

Tight junctions

Representative site: Brain.

A different barrier architecture is encountered.

Exact extravasation mechanisms remain incompletely understood.

Slide 53 · What remains uncertain about extravasation

The detailed mechanisms are not fully resolved.

Mechanisms may vary between fenestrated and tightly joined endothelium.

A single universal model is therefore not justified.

Avoid presenting a specific route across all organ endothelia as established.

Slide 54 · Survival after arrival need not mean outgrowth

Distant persistence

Tumor cells can remain viable at distant sites.

Growth may be absent or clinically occult.

Productive colonization

Tumor cells expand into a secondary mass.

Requires adaptation and supportive host interactions.

Dormancy separates arrival from overt metastasis.

Slide 55 · Tumor dormancy: A clinically important state

Disseminated tumor cells may survive yet fail to proliferate into a detectable lesion.

This dormant state can persist at a distant site.

Escape from dormancy is among the determinants of apparent metastatic deposits.

Dormancy is not the same as elimination of disseminated cells.

Slide 56 · Tumors in which dormancy is well described

Tumor example

Relevance to dormancy

Melanoma

Distant cells may persist without immediate outgrowth

Breast carcinoma

Delayed metastatic outgrowth is compatible with dormancy

Prostate carcinoma

Long-lived disseminated cells are a recognized concept

These examples; No time interval or clinical rate is implied.

Slide 57 · From dormancy to an overt metastatic lesion

Arrival in a distant organ

Survival without productive growth

Microenvironmental adaptation

Escape from dormancy

Sustained colonization

Specific triggers of escape remain incompletely characterized.

Slide 58 · Metastatic niches involve resident stromal cells

Cancer cells can secrete cytokines, growth factors, and ECM molecules.

These signals act on host stromal cells at the metastatic site.

Altered stromal responses can make the local environment more hospitable.

A metastatic deposit is an ecosystem, not only a population of cancer cells.

Slide 59 · Tumor–stroma communication is reciprocal

Tumor-secreted signals

Stromal-cell response

More permissive microenvironment

Tumor-cell survival / growth

Many additional feedback loops likely exist but are not fully delineated.

Slide 60 · Bone metastasis provides a defined feedback model

Breast cancer cell in bone

PTHRP production

Osteoblast RANKL expression

Osteoclast activation

Matrix growth factor release

IGF and TGF-β then support signaling in cancer cells.

Slide 61 · Tumor-derived PTHRP acts on osteoblasts

Metastatic breast cancer cell

Parathyroid hormone–related protein

Osteoblast response

RANKL production

PTHRP is upstream of RANKL in the cited example.

Slide 62 · RANKL activates osteoclasts

Osteoblast-derived RANKL

Osteoclast activation

Bone matrix breakdown

Release of embedded factors

This pathway recruits bone-resorbing cells to support the metastatic niche.

Slide 63 · Osteoblasts and osteoclasts play different roles

Osteoblast

Responds to tumor-secreted PTHRP.

Increases RANKL expression.

Osteoclast

Activated by RANKL.

Degrades bone matrix and frees embedded factors.

Keep the direction of the signaling cascade explicit.

Slide 64 · Bone matrix releases tumor-supporting factors

Osteoclast-driven matrix degradation

Liberation of IGF and TGF-β

Receptor engagement on cancer cells

Growth / survival signaling

These factors provide a route from host bone resorption back to cancer cells.

Slide 65 · The bone metastatic niche is a positive loop

Tumor-secreted PTHRP activates an osteoblast–osteoclast circuit.

Osteoclastic bone degradation releases matrix-bound growth factors.

Growth-factor signals support cancer-cell survival and expansion.

The loop illustrates reciprocal tumor–host conditioning, not a drug-treatment guideline.

Slide 66 · Anatomic delivery and niche growth are separable

Delivery to bone

Cancer cells must circulate and reach the skeleton.

Adhesion / extravasation are still required.

Growth within bone

Tumor and host bone cells exchange signals.

Bone-resorption products support malignant growth.

Reaching bone does not establish the PTHRP–RANKL loop by itself.

Slide 67 · Application: A colon primary with liver deposits

A patient with colon carcinoma develops metastatic deposits in the liver.

1. What anatomical feature helps explain this distribution?

2. Why does first-pass delivery not prove colonization?

Slide 68 · Interpretation: Colon carcinoma and liver

Portal venous drainage explains frequent initial delivery to the liver.

Tumor cells must still survive, arrest, extravasate, and proliferate.

The vascular pathway explains opportunity; Colonization requires tumor–organ compatibility.

This pattern exemplifies, rather than exhausts, metastatic routing.

Slide 69 · Application: Breast carcinoma with bone disease

A patient with breast carcinoma develops an enlarging secondary lesion in bone.

1. Which tumor-secreted factor can initiate the local feedback loop?

2. Which host cell releases matrix-embedded growth factors indirectly?

Slide 70 · Interpretation: The bone microenvironment

Cancer-cell PTHRP stimulates osteoblast RANKL production.

RANKL activates osteoclast-mediated matrix degradation.

IGF and TGF-β released from matrix stimulate cancer-cell signaling.

This example shows reciprocal growth promotion in a permissive niche.

Slide 71 · Application: Viable cells but no visible lesion

Disseminated malignant cells are present, but no progressively enlarging distant deposit is evident.

1. Which biological state may explain this observation?

2. What additional transition is needed for clinically apparent metastasis?

Slide 72 · Interpretation: Dormancy versus outgrowth

Tumor dormancy allows survival in a distant tissue without productive growth.

Escape from dormancy is required for expansion into an overt deposit.

This distinction helps explain why dissemination and clinical metastasis diverge.

The molecular trigger of dormancy escape is not established in the source.

Slide 73 · Application: Metastasis despite atypical drainage

A cancer disproportionately involves an organ not readily predicted by first-pass blood flow.

1. What mechanisms beyond anatomy can explain the tropism?

2. Why might a richly perfused tissue remain metastasis-poor?

Slide 74 · Interpretation: Tropism and nonpermissive soil

Endothelial adhesion ligands and tissue chemokines may guide tumor-cell homing.

The local microenvironment may favor or resist subsequent growth.

Skeletal muscle and spleen illustrate vascular abundance without high colonization.

Tropism reflects both cell-intrinsic properties and host-organ biology.

Slide 75 · Distinguish the principal stages at a glance

Stage

Core question

Necessary biological task

Circulation

Can tumor cells survive?

Resist shear, anoikis, host defenses

Arrest and homing

Where do cells stop?

Drainage plus specific tissue interactions

Extravasation

Can cells enter the tissue?

Cross endothelium and basement membrane

Colonization

Can cells establish growth?

Adapt, shape niche, leave dormancy

A tumor cell must successfully navigate several non-equivalent barriers.

Slide 76 · Key mechanistic conclusions

Clusters, platelet interactions, and possible fibrin deposition can aid circulation.

Vascular anatomy, receptor–ligand tropism, and tissue “soil” determine destination.

Extravasation is followed by an additional, often restrictive, growth challenge.

Dormancy and tumor–stroma loops explain the gap between arrival and outgrowth.

The metastatic cascade is a cooperative tumor–host process.